Loading...
Market
Which significant milestone will MRT-6160 achieve by end of 2025?
2
Resolution / Starting Odds
Progress to Phase 2 • 25%
Significant efficacy results • 25%
Safety concerns emerge • 25%
No significant milestone • 25%
Clinical trial updates and press releases from Monte Rosa Therapeutics
Story
Monte Rosa and Novartis Sign $150M Global License Agreement for MRT-6160 with $2.2B Milestone
Oct 28, 2024, 11:30 AM
Monte Rosa Therapeutics has announced a global license agreement with Novartis to advance T and B cell-modulating VAV1-directed molecular glue degraders. Novartis has committed $150 million upfront, with potential milestone payments that could exceed $2.2 billion, including $2.1 billion downstream. The deal aims to further develop Monte Rosa's MRT-6160, which is currently in Phase 1 trials. This agreement is part of Monte Rosa's broader strategy, which includes a recent collaboration with Roche to target previously undruggable cancer and neurological disease targets. Monte Rosa's CEO is Markus Warmuth, with Filip Janku as Chief Medical Officer and Jocelyn Castle as Chief Data and Information Officer. The upfront payment is half of Monte Rosa's market cap. Monte Rosa's platform/discovery engine is called QuEEN (Quantitative & Engineered Elimination of Neosubstrates).
View original story
Similar markets
Trial halted • 25%
Limited efficacy • 25%
Moderate efficacy • 25%
High efficacy • 25%
Initiation of Phase 4 trial • 25%
Regulatory approval in Europe • 25%
Launch of a new indication study • 25%
No major milestone announced • 25%
Phase 1 completion • 25%
Phase 2 initiation • 25%
Partnership announcement • 25%
Other milestone • 25%
New clinical trial initiation • 25%
Partnership with another pharma company • 25%
FDA approval • 25%
Acquisition by Lilly • 25%
Initial construction completed • 33%
First production output • 33%
Secured major European client • 34%
Adoption in top AI research labs • 25%
Integration in top tech companies' products • 25%
Winning a major AI benchmark contest • 25%
Other • 25%
Completion of site investigations • 25%
Submission of application under the ADVANCE Act • 25%
Approval of application under the ADVANCE Act • 25%
No major milestone achieved • 25%
First commercial flight • 25%
First military application • 25%
First passenger service • 25%
None of the above • 25%
Launch of beta version • 25%
Integration with top blockchain • 25%
Partnership with AI research institution • 25%
Other significant milestone • 25%
Achieving 95% accuracy in basic tasks • 25%
Integration into commercial robots • 25%
Adoption in healthcare • 25%
Other • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Regulatory approval submission • 25%
No significant milestone • 25%